Prior information notice
This notice is a call for competition
Section I: Contracting
authority
I.1) Name and addresses
Porton Biopharma Ltd
Salisbury
UK
E-mail: jeff.pike@portonbiopharma.com
NUTS: UKK15
Internet address(es)
Main address: https://portonbiopharma.bravosolution.co.uk
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.3) Communication
Access to the procurement documents is restricted. Further information can be obtained at:
https://portonbiopharma.bravosolution.co.uk
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://portonbiopharma.bravosolution.co.uk
Tenders or requests to participate must be sent to the abovementioned address
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
PBL — 150111 QC and Dev Lab Block Design Services
II.1.2) Main CPV code
71220000
II.1.3) Type of contract
Services
II.1.4) Short description
Please note that this procurement is restricted and organisations will have to complete a CDA to access further information.
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.3) Place of performance
NUTS code:
UKK15
II.2.4) Description of the procurement
4) Scope of Service:
4.1) Design Stage 2 — concept (BIM level 2);
4.2) Design Stage 3 — Developed design (BIM level 2);
4.3) Town and Country Planning;
4.4) Principal Designer;
4.5) Construction Tender (Single stage, NEC Option A);
4.6) Construction Monitoring (commissioning and handover).
Please see Bravo portal for further details.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Restricted procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.2) Time limit for receipt of expressions of interest
Date:
31/05/2019
Local time: 17:00
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
Section VI: Complementary information
VI.2) Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
VI.4) Procedures for review
VI.4.1) Review body
Porton Biopharma Ltd
Salisbury
UK
VI.5) Date of dispatch of this notice
25/04/2019